Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy - PubMed (original) (raw)
Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy
R Chibber et al. Diabetologia. 1997 Feb.
Abstract
The toxic effects of advanced glycation end products (AGEs) on bovine retinal capillary pericytes (BRP) and endothelial cells (BREC) were studied. AGE-modified bovine serum albumin (AGE-BSA) was toxic to BRP. At a concentration of 500 micrograms/ml it reduced the BRP number to 48 +/- 3% (p < 0.05) of untreated controls, as determined by cell counting with haemocytometer. AGE-BSA was also toxic to bovine aortic endothelial cells (BAEC) reducing cell number to 84 +/- 3.1% of untreated controls. Under similar conditions, low concentrations (62.5 micrograms/ml) of AGE-BSA were mitogenic to BREC increasing the cell proliferation to 156 +/- 11% (p < 0.05) above that of untreated controls. At a higher dose of 500 micrograms/ml AGE-BSA decreased the proliferation of BREC to 85 +/- 6% of untreated controls. Immunoblot analysis demonstrated that BRP and BREC express the p60 AGE-receptor. Retinal capillary bed from the human also stained positively for the p60 AGE-receptor. Addition of 0.25 micrograms/ml of p60 AGE-receptor antibody was able to block the effects of AGE-BSA on BRP and BREC. The level of binding of [125I]-labelled AGE-BSA to the cell surface was small but significant among the three cell types. There was also an increase in the internalized pool of radioligand in BRP and BREC but this was very much lower than in BAEC. In all the cell types the internalized pool of [125I]-labelled AGE-BSA was much larger than the amount associated with the cell surface. Degradation products were not detected in the media over the 24-h incubation of the cells with [125I]AGE-BSA. The binding of [125I]-labelled AGE-BSA to the cell surface was prevented by the addition of p60 AGE-receptor. These results suggest that the interaction of AGE-modified proteins with the membrane-bound AGE-receptor may play an important role in the pathogenesis of diabetic retinopathy.
Similar articles
- Effect of advanced glycation end products on accelerated apoptosis of retinal capillary cells under in vitro conditions.
Kowluru RA. Kowluru RA. Life Sci. 2005 Jan 14;76(9):1051-60. doi: 10.1016/j.lfs.2004.10.017. Life Sci. 2005. PMID: 15607333 - Advanced glycation end products induce specific glycoprotein alterations in retinal microvascular cells.
Rellier N, Ruggiero D, Lecomte M, Lagarde M, Wiernsperger N. Rellier N, et al. Biochem Biophys Res Commun. 1997 Jun 18;235(2):281-5. doi: 10.1006/bbrc.1997.6768. Biochem Biophys Res Commun. 1997. PMID: 9199182 - Intracellular protein glycation in cultured retinal capillary pericytes and endothelial cells exposed to high-glucose concentration.
Chibber R, Molinatti PA, Kohner EM. Chibber R, et al. Cell Mol Biol (Noisy-le-grand). 1999 Feb;45(1):47-57. Cell Mol Biol (Noisy-le-grand). 1999. PMID: 10099839 - [Role of advanced glycation end products and activation of PKC in diabetic retinopathy].
Kaji Y, Oshika T. Kaji Y, et al. Nihon Rinsho. 2005 Jun;63 Suppl 6:188-93. Nihon Rinsho. 2005. PMID: 15999705 Review. Japanese. No abstract available. - [Diabetic retinopathy: pathogenesis, risk factors, clinical picture, classification].
Malenfant M. Malenfant M. Bull Soc Belge Ophtalmol. 1995;256:11-23. Bull Soc Belge Ophtalmol. 1995. PMID: 8581223 Review. French.
Cited by
- Safety and efficacy profile of intravitreal ranibizumab vs dexamethasone in treatment of naïve diabetic macular edema.
Mahapatra SK, Parhi A, Shree P, Mohanty A. Mahapatra SK, et al. Indian J Ophthalmol. 2024 Jan 1;72(Suppl 1):S106-S110. doi: 10.4103/IJO.IJO_767_23. Epub 2023 Dec 22. Indian J Ophthalmol. 2024. PMID: 38131551 Free PMC article. - Effects of long-term treatment with ranirestat, a potent aldose reductase inhibitor, on diabetic cataract and neuropathy in spontaneously diabetic torii rats.
Ota A, Kakehashi A, Toyoda F, Kinoshita N, Shinmura M, Takano H, Obata H, Matsumoto T, Tsuji J, Dobashi Y, Fujimoto WY, Kawakami M, Kanazawa Y. Ota A, et al. J Diabetes Res. 2013;2013:175901. doi: 10.1155/2013/175901. Epub 2013 Mar 13. J Diabetes Res. 2013. PMID: 23671855 Free PMC article. - Advanced glycation end products and diabetic complications.
Singh VP, Bali A, Singh N, Jaggi AS. Singh VP, et al. Korean J Physiol Pharmacol. 2014 Feb;18(1):1-14. doi: 10.4196/kjpp.2014.18.1.1. Epub 2014 Feb 13. Korean J Physiol Pharmacol. 2014. PMID: 24634591 Free PMC article. Review. - Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms.
Stirban A, Gawlowski T, Roden M. Stirban A, et al. Mol Metab. 2013 Dec 7;3(2):94-108. doi: 10.1016/j.molmet.2013.11.006. eCollection 2014 Apr. Mol Metab. 2013. PMID: 24634815 Free PMC article. Review. - Neuroprotection as a Therapeutic Target for Diabetic Retinopathy.
Hernández C, Dal Monte M, Simó R, Casini G. Hernández C, et al. J Diabetes Res. 2016;2016:9508541. doi: 10.1155/2016/9508541. Epub 2016 Mar 31. J Diabetes Res. 2016. PMID: 27123463 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical